Luminex and Bio-Techne announced the signing of a new distribution and supply agreement through 2020.
This agreement extends the relationship between the two companies for immunoassay development and commercialization of Bio-Techne biological content using the Luminex testing platform.
Furthermore the agreement allows Bio-Techne to distribute Luminex multiplexing instrumentation, including the Luminex 200, FLEXMAP 3D and the MAGPIX platforms in major markets worldwide.
"We are very pleased to broaden our relationship with Bio-Techne, a leading global player in the research, diagnostics and clinical controls markets. We believe enabling Bio-Techne to develop assay content and distribute Luminex multiplexing instruments will aid our goal of providing laboratories of all sizes access to multiplexing solutions for a range of applications," said Todd Bennett, VP, Global Sales and Customer Operations, Luminex Corporation.
"With its global scope, Bio-Techne is an ideal partner that can ensure our advanced multiplexing solutions reach the right scientists and researchers. This partnership will help accelerate science and improve the efficiency of disease-related research around the world."
"We have been a partner with Luminex for many years and given our strong market position in immunoassay applications, it is logical for Bio-Techne to continue to support our customers with complete customized workflow solutions, including instruments. This is consistent with the Company’s strategic direction of providing full solutions in the Life Science research space, including both biological content and instruments," said Gerry Andros, VP of Sales for Bio-Techne Corporation.
Financial terms were not disclosed.
Luminex offers three multiplex instruments enabling laboratories to choose a platform that fits their throughput and flexibility needs. MAGPIX is the simplest, most affordable, and most compact of Luminex’s xMAP instruments.